{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:39:05Z","timestamp":1794429545187,"version":"4.9.1"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Immune-mediated adverse drug reactions (IM-ADRs) are many times more common in HIV-infected patients. Usual offending drugs include antiretroviral and antiinfectives, but the burden of specific drug IM-ADRs is population-specific; changing as new and fixed dose combinations enter the market, and drug-resistance patterns demand. This review considers recent literature on epidemiology, mechanisms, clinical management and prevention of IM-ADRs amongst persons living with HIV\/AIDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Epidemiological studies continue to describe high rates of delayed hypersensitivity to known offenders, as well as similar reactions in preexposure prophylaxis. IM-ADRs to oral and injectable integrase strand transfer inhibitors are reported with expanding use. The clinical spectrum and management of IM-ADRs occurring in HIV-infected populations is similar to uninfected; with exceptions such as a recently described severe delayed efavirenz DILI with high mortality. Furthermore, the context can be unique, such as the lower than expected mortality in a Stevens\u2013Johnson syndrome and toxic epidermal necrolysis (SJS\/TEN) cohort from a HIV\/TB high burden setting. Programmatic data showing the near complete elimination of Abacavir drug hypersensitivity syndrome following implementation of HLA-B57:01 screening is a stellar example of how prevention is possible with mechanistic insight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>IM-ADRs remain a challenge in persons living with HIV. The complexities posed by polypharmacy, overlapping drug toxicities, drug interactions, overlap of IM-ADRs with other diseases, limited alternative drugs, and vulnerable patients with advanced immunosuppression with high mortality, necessitate increased use of drug provocation testing, treat-through and desensitization strategies. There is an urgent need for improved diagnostics and predictive biomarkers for prevention, or to guide treat-through, rechallenge and desensitization approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aci.0000000000000545","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:36:58Z","timestamp":1559176618000},"page":"272-282","source":"Crossref","is-referenced-by-count":52,"title":["Drug hypersensitivity in HIV infection"],"prefix":"10.1097","volume":"19","author":[{"given":"Jonny","family":"Peter","sequence":"first","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town"},{"name":"Allergy and Immunology Unit, University of Cape Town Lung Institute"},{"name":"Combined Drug Allergy Clinic, Groote Schuur Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuti","family":"Choshi","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town"},{"name":"Allergy and Immunology Unit, University of Cape Town Lung Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe J.","family":"Lehloenya","sequence":"additional","affiliation":[{"name":"Combined Drug Allergy Clinic, Groote Schuur Hospital"},{"name":"Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jcpt.12702","article-title":"Mortality from adverse drug reaction-related hospitalizations in south-west Ethiopia: a cross-sectional study","volume":"43","author":"Angamo","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","article-title":"Cutaneous disease and drug reactions in HIV infection","volume":"328","author":"Coopman","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(18)32218-9","article-title":"Antibiotic allergy","volume":"393","author":"Blumenthal","year":"2019","journal-title":"Lancet"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"e000227","DOI":"10.1136\/bmjgh-2016-000227","article-title":"UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on \u2018Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades\u2019","volume":"2","author":"Bain","year":"2017","journal-title":"BMJ Glob Health"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3851\/IMP3031","article-title":"Key data from the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV","volume":"21","author":"Coughlan","year":"2016","journal-title":"Antivir Ther"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"e0171596","DOI":"10.1371\/journal.pone.0171596","article-title":"Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naive HIV-positive patients receiving nonnucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/pds.4067","article-title":"Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis","volume":"25","author":"Stewart","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"e94854","DOI":"10.1371\/journal.pone.0094854","article-title":"Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?","volume":"9","author":"Sarfo","year":"2014","journal-title":"PLoS One"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S2352-3018(17)30156-X","article-title":"Daily and nondaily preexposure prophylaxis in African women (HPTN 067\/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2196","article-title":"Abacavir hypersensitivity reaction reporting rates during a decade of HLA-B\u22175701 screening as a risk-mitigation measure","volume":"39","author":"Stainsby","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0956462417734099","article-title":"Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature","volume":"29","author":"Wang","year":"2018","journal-title":"Int J STD AIDS"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cix096","article-title":"Association of the HLA-B\u221753:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome during treatment of HIV infection with raltegravir","volume":"64","author":"Thomas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciy082","article-title":"Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine","volume":"67","author":"Brooks","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R15-20230828","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky564","article-title":"Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000\u200acopies\/ml: week 48 outcomes from ACTG 5353","author":"Nyaku","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000\u200acopies\/ml","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"e1002690","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7196\/SAMJ.7479","article-title":"Cutaneous adverse drug reactions caused by FDCAs - we need to characterise and manage them urgently","volume":"103","author":"Lehloenya","year":"2013","journal-title":"S Afr Med J"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5415\/apallergy.2014.4.1.54","article-title":"Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management","volume":"4","author":"Yunihastuti","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/ACI.0b013e32825ea68a","article-title":"Drug hypersensitivity in HIV","volume":"7","author":"Phillips","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ACI.0000000000000462","article-title":"Management of adverse reactions to first-line tuberculosis antibiotics","volume":"18","author":"Nagarajan","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5588\/ijtld.16.0425","article-title":"CD4 count and risk of antituberculosis drug-associated cutaneous reactions in HIV-infected Thai patients","volume":"21","author":"Boonyagars","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"6216193","DOI":"10.1155\/2017\/6216193","article-title":"Prevalence and clinical profile of drug eruptions among antiretroviral therapy-exposed HIV infected people in Yaounde, Cameroon","volume":"2017","author":"Kouotou","year":"2017","journal-title":"Dermatol Res Pract"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3389\/fphar.2018.00727","article-title":"Appropriateness of cotrimoxazole prophylactic therapy among HIV\/AIDS patients in public hospitals in Eastern Ethiopia: a retrospective evaluation of clinical practice","volume":"9","author":"Sisay","year":"2018","journal-title":"Front Pharmacol"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1086\/521112","article-title":"Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary","volume":"196","author":"Murphy","year":"2007","journal-title":"J Infect Dis"},{"key":"R29-20230828","first-page":"831","article-title":"Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone","volume":"18","author":"Holtzer","year":"1998","journal-title":"Pharmacotherapy"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/00002030-200007280-00032","article-title":"Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?","volume":"14","author":"Soriano","year":"2000","journal-title":"AIDS"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1468-1293.2006.00396.x","article-title":"Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash","volume":"7","author":"Manosuthi","year":"2006","journal-title":"HIV Med"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cod.12508","article-title":"Severe reaction to emtricitabine and lamiduvine: evidence of cross-reactivity","volume":"74","author":"Suarez-Lorenzo","year":"2016","journal-title":"Contact Dermatitis"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00042560-199502000-00004","article-title":"Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells","volume":"8","author":"Rieder","year":"1995","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2230.1997.tb01038.x","article-title":"Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR)","volume":"22","author":"Smith","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev-pharmtox-010818-021818","article-title":"Applications of Immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions","volume":"59","author":"Karnes","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"e0145261","DOI":"10.1371\/journal.pone.0145261","article-title":"Dysregulated immune activation in second-line HAART HIV+ patients is similar to that of untreated patients","volume":"10","author":"Espindola","year":"2015","journal-title":"PLoS One"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7883\/yoken.JJID.2016.075","article-title":"Association of IL10, IL4, IFNG, and CTLA4 gene polymorphisms with efavirenz hypersensitivity reaction in patients infected with human immunodeficiency virus","volume":"70","author":"de Oliveira Rodrigues","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","article-title":"The significance of interferon-\u03b3 in HIV-1 pathogenesis, therapy, and prophylaxis","volume":"4","author":"Roff","year":"2014","journal-title":"Front Immunol"},{"issue":"(Suppl 72)","key":"R41-20230828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1398-9995.57.s72.15.x","article-title":"Deciphering the immune pathomechanism of cutaneous drug reactions","volume":"57","author":"Pichler","year":"2002","journal-title":"Allergy"},{"issue":"(3 Suppl)","key":"R42-20230828","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/eji.1830241146","article-title":"Selective regulation of ICAM-1 and major histocompatibility complex class I and II molecule expression on epidermal Langerhans cells by some of the cytokines released by keratinocytes and T cells","volume":"24","author":"Chang","year":"1994","journal-title":"Eur J Immunol"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emm.1998.1","article-title":"Cytokine regulation of expression of class I MHC antigens","volume":"30","author":"Raval","year":"1998","journal-title":"Exp Mol Med"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e32835d85b4","article-title":"Impact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa","volume":"27","author":"Hayes","year":"2013","journal-title":"Aids"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10875-010-9449-7","article-title":"Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes","volume":"30","author":"Parish","year":"2010","journal-title":"J Clin Immunol"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jaad.2013.12.025","article-title":"HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4(+) T cells","volume":"70","author":"Yang","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/ACI.0b013e32832d565c","article-title":"Role of T cells in nonimmediate allergic drug reactions","volume":"9","author":"Rozieres","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tox.2006.01.018","article-title":"Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso","volume":"222","author":"Lavergne","year":"2006","journal-title":"Toxicology"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1074\/jbc.275.5.3693","article-title":"Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice","volume":"275","author":"Choi","year":"2000","journal-title":"J Biol Chem"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1755-8794-5-32","article-title":"Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV\/AIDS patients","volume":"5","author":"Wang","year":"2012","journal-title":"BMC Med Genomics"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.tiv.2009.11.020","article-title":"An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells","volume":"24","author":"Hosomi","year":"2010","journal-title":"Toxicol In Vitro"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2016.08.010","article-title":"Immunogenicity of trimethoprim\/sulfamethoxazole in a macaque model of HIV infection","volume":"368\u2013369","author":"Wong","year":"2016","journal-title":"Toxicology"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00042560-199812150-00009","article-title":"A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group","volume":"19","author":"Walmsley","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0163-4453(97)91578-4","article-title":"N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients","volume":"35","author":"Akerlund","year":"1997","journal-title":"J Infect"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/QAI.0b013e31827ca50f","article-title":"Associations between HLA-DRB1\u22170102, HLA-B\u22175801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa","volume":"62","author":"Phillips","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1038\/s41598-017-08876-0","article-title":"Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles","volume":"7","author":"Pavlos","year":"2017","journal-title":"Sci Rep"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/jac\/dky190","article-title":"Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals","volume":"73","author":"de Almeida","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R60-20230828","first-page":"197","article-title":"Cutaneous adverse drug reaction in human immunodeficiency virus","author":"Lehloenya","year":"2018","journal-title":"Advances in the diagnosis and managment of cutaneous adverse drug reactions"},{"key":"R61-20230828","first-page":"10","article-title":"Liver involvement complicating SJS\/TEN in an HIV endemic setting","volume":"8","author":"Haitembu","year":"2018","journal-title":"Clin Translat Allergy"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jaip.2018.10.053","article-title":"Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies","volume":"7","author":"Lehloenya","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"key":"R64-20230828","first-page":"S69","article-title":"The rate of hypersensitivity reactions to abacavir is similar in under-represented populations and incarcerated subjects","volume":"14","author":"Hernandez","year":"2000v","journal-title":"AIDS"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: an update","volume":"42","author":"Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1093\/jac\/dkt287","article-title":"Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases","volume":"68","author":"Isaacs","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R67-20230828","article-title":"Oxidative stress, first-line antituberculosis drug-induced hepatotoxicity","volume":"62","author":"Yew","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"e94271","DOI":"10.1371\/journal.pone.0094271","article-title":"Evaluation of patterns of liver toxicity in patients on antiretroviral and antituberculosis drugs: a prospective four arm observational study in Ethiopian patients","volume":"9","author":"Yimer","year":"2014","journal-title":"PLoS One"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1097\/QAD.0000000000001084","article-title":"Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa","volume":"30","author":"Sonderup","year":"2016","journal-title":"AIDS"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256308","article-title":"Successful translation of pharmacogenetics into the clinic: the abacavir example","volume":"13","author":"Phillips","year":"2009","journal-title":"Mol Diagn Ther"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1473-3099(07)70262-1","article-title":"Is it safe to switch between efavirenz and nevirapine in the event of toxicity?","volume":"7","author":"Mehta","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QCO.0000000000000323","article-title":"Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity","volume":"29","author":"Konvinse","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"R74-20230828","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjd.14492","article-title":"Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons","volume":"175","author":"Lehloenya","year":"2016","journal-title":"Br J Dermatol"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.5588\/ijtld.10.0698","article-title":"Outcomes of reintroducing antituberculosis drugs following cutaneous adverse drug reactions","volume":"15","author":"Lehloenya","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"R76-20230828","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R77-20230828","article-title":"Treatment can be continued for mild cutaneous reactions associated with efavirenz","author":"Isaacs","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11882-018-0791-9","article-title":"Sulfonamide drug allergy","volume":"18","author":"Dorn","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"R79-20230828","first-page":"CD005646","article-title":"Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients with previous history of hypersensitivity to cotrimoxazole","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jac\/dkn292","article-title":"Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection","volume":"62","author":"Borras-Blasco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R81-20230828","doi-asserted-by":"crossref","first-page":"RRN1203","DOI":"10.1371\/currents.RRN1203","article-title":"HLA-B\u22175701 testing to predict abacavir hypersensitivity","volume":"2","author":"Ma","year":"2010","journal-title":"PLoS Curr"},{"key":"R82-20230828","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"R83-20230828","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"Martin-Carbonero","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R84-20230828","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1097\/00002030-200409030-00019","article-title":"Lichenoid drug eruption to tenofovir in an HIV\/hepatitis B virus co-infected patient","volume":"18","author":"Woolley","year":"2004","journal-title":"AIDS"},{"key":"R85-20230828","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/QAD.0b013e32811ebf9e","article-title":"Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases","volume":"21","author":"Lockhart","year":"2007","journal-title":"AIDS"},{"key":"R86-20230828","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4103\/0253-7613.100407","article-title":"First reported case of tenofovir-induced photoallergic reaction","volume":"44","author":"Verma","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"R87-20230828","first-page":"85","article-title":"A retrospective study of spectrum of nevirapine induced cutaneous drug reactions in HIV positive patients","volume":"12","author":"Budamakuntla","year":"2015","journal-title":"J US-China Med Sci"},{"key":"R88-20230828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s15010-004-4034-8","article-title":"Efavirenz-associated Stevens-Johnson syndrome","volume":"32","author":"Colebunders","year":"2004","journal-title":"Infection"},{"key":"R89-20230828","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2125.2010.03784.x","article-title":"Hypersensitivity reactions to HIV therapy","volume":"71","author":"Chaponda","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"(Suppl 3)","key":"R90-20230828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/2045-7022-4-S3-P104","article-title":"Hypersensitivity to antiretroviral drugs a case report","volume":"4","author":"Sousa","year":"2014","journal-title":"Clin Translat Allergy"},{"key":"R91-20230828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7196\/SAMJ.7479","article-title":"Cutaneous adverse drug reactions caused by FDCAs \u2013 we need to characterise and manage them urgently","volume":"103","author":"Lehloenya","year":"2013","journal-title":"S Afr Med J"},{"key":"R92-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1939-4551-6-18","article-title":"Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy","volume":"6","author":"S\u00e1nchez-Borges","year":"2013","journal-title":"World Allergy Organ J"},{"key":"R93-20230828","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2340\/00015555-1268","article-title":"Hypersensitivity reactions to dapsone: a systematic review","volume":"92","author":"Lorenz","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"R94-20230828","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.anai.2012.04.005","article-title":"Graded challenge protocol for fluconazole hypersensitivity in a patient with cryptococcal pneumonitis","volume":"108","author":"Rankin","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R95-20230828","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4103\/0976-500X.99445","article-title":"Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection","volume":"3","author":"George","year":"2012","journal-title":"J Pharmacol Pharmacother"},{"key":"R96-20230828","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/apc.2017.0116","article-title":"Substantially higher and earlier occurrence of anti-tuberculosis drug-related adverse reactions in HIV coinfected tuberculosis patients: a matched-cohort study","volume":"31","author":"Matono","year":"2017","journal-title":"AIDS Patient Care STDS"},{"key":"R97-20230828","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to antituberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R98-20230828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2334-14-23","article-title":"Acute kidney injury due to antituberculosis drugs: a five-year experience in an aging population","volume":"14","author":"Chang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R99-20230828","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.5588\/ijtld.11.0187","article-title":"Multiple drug hypersensitivity reactions to antituberculosis drugs: five cases in HIV-infected patients","volume":"16","author":"Lehloenya","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R100-20230828","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/3.2.115","article-title":"Adverse reactions to rifampicin in antituberculosis regimens","volume":"3","author":"Girling","year":"1977","journal-title":"J Antimicrob Chemother"},{"key":"R101-20230828","doi-asserted-by":"crossref","first-page":"ofw130","DOI":"10.1093\/ofid\/ofw130","article-title":"Therapeutic trial of rifabutin after rifampicin-associated DRESS syndrome in tuberculosis-human immunodeficiency virus coinfected patients","volume":"3","author":"Lehloenya","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R102-20230828","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0536.2002.460610.x","article-title":"Delayed-type hypersensitivity reaction to ethambutol and isoniazid","volume":"46","author":"Bakkum","year":"2002","journal-title":"Contact Dermatitis"},{"key":"R103-20230828","first-page":"227","article-title":"Severe cutaneous adverse reactions due to isoniazid in a HIV positive patient","volume":"84","author":"Viswanath","year":"2012","journal-title":"Indian J Lepr"},{"key":"R104-20230828","first-page":"143","article-title":"Two years review of cutaneous adverse drug reaction from first line antituberculous drugs","volume":"62","author":"Tan","year":"2007","journal-title":"Med J Malaysia"},{"key":"R105-20230828","first-page":"195","article-title":"A case of Stevens-Johnson's syndrome caused by ethambutol","volume":"19","author":"Surjapranata","year":"1979","journal-title":"Paediatr Indones"},{"key":"R106-20230828","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/archinte.1981.00340130115027","article-title":"Ethambutol-induced toxic epidermal necrolysis","volume":"141","author":"Pegram","year":"1981","journal-title":"Arch Intern Med"},{"key":"R107-20230828","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1183\/09031936.95.08050866","article-title":"Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement","volume":"8","author":"Wong","year":"1995","journal-title":"Eur Respir J"},{"key":"R108-20230828","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.det.2013.11.004","article-title":"Clinical presentations of severe cutaneous drug reactions in HIV-infected Africans","volume":"32","author":"Lehloenya","year":"2014","journal-title":"Dermatol Clin"},{"key":"R109-20230828","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"key":"R110-20230828","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5415\/apallergy.2014.4.3.156","article-title":"A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy","volume":"4","author":"Thong","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"R111-20230828","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2018.01.006","article-title":"Successful drug desensitization in patients with delayed-type allergic reactions to antituberculosis drugs","volume":"68","author":"Siripassorn","year":"2018","journal-title":"Int J Infect Dis"},{"key":"R112-20230828","first-page":"1152","article-title":"Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population","volume":"72","author":"Carr","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130832-201908000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T21:08:09Z","timestamp":1694898489000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130832-201908000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000545","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}